壹生资讯-2020 CSCO-CMT胃肠间质瘤领域年度进展评选活动开始啦！

+86
获取验证码

记住我忘记密码

还没有账号？立即注册

常用国家/地区ABCDEFGHIJKLMNOPQRSTUVWXYZ

手机号已经完成验证，请完善个人资料！

壹生身份认证协议书

本项目是由壹生提供的专业性学术分享，仅面向医疗卫生专业人士。我们将收集您是否是医疗卫生专业人士的信息，仅用于资格认证，不会用于其他用途。壹生作为平台及平台数据的运营者和负责方，负责平台和本专区及用户相关信息搜集和使用的合规和保护。
本协议书仅为了向您说明个人相关信息处理目的，向您单独征求的同意，您已签署的壹生平台《壹生用户服务协议》和《壹生隐私政策》，详见链接：
壹生用户服务协议：
https://apps.medtrib.cn/html/serviceAgreement.html
壹生隐私政策：
https://apps.medtrib.cn/html/p.html
如果您是医疗卫生专业人士，且点击了“同意”，表明您作为壹生的注册用户已授权壹生平台收集您是否是医疗卫生专业人士的信息，可以使用本项服务。
如果您不是医疗卫生专业人士或不同意本说明，请勿点击“同意”，因为本项服务仅面向医疗卫生人士，以及专业性、合规性要求等因素，您将无法使用本项服务。

同意

拒绝

同意

拒绝

知情同意书

同意

不同意并跳过

工作人员正在审核中，
请您耐心等待

审核未通过

重新提交

完善信息

{{ item.question }}

确定

收集问题

{{ item.question }}

确定

您已通过HCP身份认证和信息审核

(

5

s)

2020 CSCO-CMT胃肠间质瘤领域年度进展评选活动开始啦！

2020-11-27作者：金金资讯

消化系统肿瘤

微信图片_20201127162817.png

时光荏苒，2020年已接近尾声，又到了年终总结、盘点的重要时刻。回首2020，国际胃肠间质瘤（GIST）领域专家学者活跃在各大舞台，牵头开展的临床研究也如火如荼，在临床、影像、病理、基础转化研究以及规范化诊疗领域均取得了巨大的进展。

值此辞旧迎新的重要时刻，由中国医学论坛报社(CMT）编辑部精心策划、CSCO 胃肠道间质瘤专家委员会大力支持的“CSCO GIST专栏”即将完美收官。

为迎接2021新的开始，CSCO与CMT再度携手，联合举办“胃肠间质瘤领域年度进展评选”活动！

活动详情

本次参与评选的20项进展包括17项在国际权威期刊发表的研究（综述），中国原创的GIST指南及共识各1篇，NCCN GIST指南1篇。我们将采用网络读者投票的模式，选出投票最多的前十项成为2020 CSCO-CMT GIST十大年度进展，快来动动手指，为您心中的“大事件”投上宝贵一票吧！

投票时间

即日起至2020年12月5日12:00

投票规则

每位用户每日可以投2次，在微信端点开链接可以投1次；下载中国医学论坛报社官方APP“壹生”，成功注册可以在“壹生”APP端投票链接投1次。每次投票可选择1-10项研究。

结果公布

最终评选结果将于2020年12月12日壹生APP直播会议“第二届CSCO再鼎肿瘤学高峰论坛暨国际胃肠间质瘤高峰论坛”公布，敬请期待！

欢迎投票，选出您心中的“大事件”！

{"attendFlag":0,"createTime":1606453807000,"dayEndTime":"23:45","dayStartTime":"00:00","endTime":1607140800000,"hideVotenum":false,"id":110097422,"isBindWx":0,"isOpenValidate":0,"items":[{"createTime":1606453807000,"filepathIds":"","id":2487,"imagePattern":0,"images":[],"isMultiple":1,"isNecessary":0,"maxChoicesNum":10,"minChoicesNum":1,"options":[{"createTime":1606453807000,"description":"应用瑞派替尼治疗进展期GIST患者的mPFS达到6.3个月（安慰剂组1.0个月），瑞派替尼显著提高了mPFS，并对现有获批治疗方案耐药的晚期GIST患者具有良好的耐受性。\nLancet Oncol. 2020 Jul;21(7):923-934. （IF：35.386）","filepathIds":"409555","id":10320,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/1872c6de-a55f-4af3-a968-95c74cbf5429.png","attr":"424_424"}],"isRight":0,"researchId":110097422,"researchItemId":2487,"title":"瑞派替尼治疗进展期GIST的INVICTUS研究：一项双盲，随机，安慰剂对照III期临床研究","userCount":1198,"userId":2763927},{"createTime":1606453807000,"description":"瑞派替尼是一种新型的KIT和PDGFRA突变激酶抑制剂，研究中接受瑞派替尼二线、三线和≥四线治疗晚期GIST患者的mPFS分别为10.7个月、8.3个月和5.5个月；12个月PFS率分别为33.5%、29.2%和21.2%；客观缓解率分别为19.4%、14.3%和7.2%。瑞派替尼用于难治性晚期GIST患者耐受良好，且无论在二线、三线还是≥四线治疗中，都展现出非常有希望的疗效前景。\nJ Clin Oncol. 2020 Oct 1;38(28):3294-3303.（IF：32.956）","filepathIds":"409556","id":10321,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/48dcd6a6-0684-474b-9e7c-abb609700dab.png","attr":"397_397"}],"isRight":0,"researchId":110097422,"researchItemId":2487,"title":"晚期胃肠间质瘤患者的KIT和PDGFRA开关控制抑制:瑞派替尼I期研究","userCount":1107,"userId":2763927},{"createTime":1606453807000,"description":"对于经开腹肿瘤完全切除术且高复发风险的GIST患者，3年伊马替尼辅助治疗的RFS和OS明显优于1年辅助治疗，3年辅助治疗可显著降低术后患者第一个10年约50%的死亡风险。\nJAMA Oncol. 2020 Aug 1;6(8):1241-1246. （IF：22.416）","filepathIds":"409557","id":10322,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/1cca66ec-8f36-46b2-abde-d2403c633841.png","attr":"393_393"}],"isRight":0,"researchId":110097422,"researchItemId":2487,"title":"伊马替尼辅助治疗高危胃肠间质瘤患者3年对照1年的生存分析：一项随机临床研究的10年随访分析","userCount":831,"userId":2763927},{"createTime":1606453807000,"description":"AZD3229在临床相关暴露下具有抑制KIT的ATP结合和A环突变的能力，能够持久抑制源自患者的GIST异种移植模型中的KIT信号。\nSci Transl Med. 2020 Apr 29; 12(541): eaaz2481. （IF：16.304）","filepathIds":"409558","id":10323,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/eab309ec-d293-4eb0-a926-1207534590aa.png","attr":"177_177"}],"isRight":0,"researchId":110097422,"researchItemId":2487,"title":"AZD3229（一种有效的KIT /PDGFRα抑制剂，用于治疗胃肠道间质瘤）的发现和药理特性","userCount":539,"userId":2763927},{"createTime":1606453807000,"description":"野生型GIST患者对林西替尼的耐受性良好。尽管9个月的临床获益率和PFS分别为40％、52％，但并未观察到客观缓解。\nClin Cancer Res. 2020 Apr 15;26(8):1837-1845. （IF：10.107）","filepathIds":"409559","id":10324,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/a4a36f88-aedc-4081-9a32-204c98c2c638.png","attr":"245_245"}],"isRight":0,"researchId":110097422,"researchItemId":2487,"title":"林西替尼 (OSI-906) 治疗成人和小儿野生型胃肠间质瘤，SARC II期研究","userCount":416,"userId":2763927},{"createTime":1606453807000,"description":"PDGFRA D842V突变约占GIST患者的5%-6%，Avapritinib对于晚期PDGFRA D842V突变型GIST初步显示出较好的抗肿瘤活性，且安全可控。\nLancet Oncol. 2020 Jul;21(7):935-946. （IF：33.752）","filepathIds":"409560","id":10325,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/9ea8553d-2a76-4333-b124-68595c0b0391.png","attr":"393_393"}],"isRight":0,"researchId":110097422,"researchItemId":2487,"title":"Avapritinib在PDGFRA D842V突变晚期GIST中的作用：多中心、开放标签、I期研究","userCount":583,"userId":2763927},{"createTime":1606453807000,"description":"手术切除的局限性GIST显微镜切缘阳性并不常见，但并不影响患者生存结果。\nSurgery. 2020 Aug 27;S0039-060(20)30461-X.（IF：3.356）","filepathIds":"409561","id":10326,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/ed5c0c0c-2c85-4a67-b8ce-817eae01a60e.png","attr":"399_399"}],"isRight":0,"researchId":110097422,"researchItemId":2487,"title":"镜下手术切缘阳性对原发性胃肠间质瘤预后有影响吗?","userCount":881,"userId":2763927},{"createTime":1606453807000,"description":"应用伊马替尼新辅助治疗（nIM）可显著缩小局限性直肠GIST的肿瘤体积。TEM联合nIM是直肠GIST患者保住肛门和保护肛门功能切实可行的治疗方法。\nSurg Endosc. 2020 Sep 23. （IF：3.149）","filepathIds":"409562","id":10327,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/8663a345-1991-4cf8-9631-585ad1cd2440.png","attr":"369_369"}],"isRight":0,"researchId":110097422,"researchItemId":2487,"title":"经肛门内镜微创手术(TEM)联合选择性伊马替尼新辅助治疗局限性直肠胃肠间质瘤的长期医学观察单中心经验","userCount":772,"userId":2763927},{"createTime":1606453807000,"description":"根据4例患者的临床观察，内镜切除结合Apollo OverStitch缝合系统，治疗直径20–40 mm的III型胃GISTs是可选择的有效治疗手段，安全性良好，但仍需更大样本量证实。\nJ Clin Med. 2020 Jun 8;9(6):1776.  （IF：5.688）","filepathIds":"409563","id":10328,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/af0e4142-d862-4927-8d50-69261ca28a42.png","attr":"379_379"}],"isRight":0,"researchId":110097422,"researchItemId":2487,"title":"对于适宜病人选择合适的内镜切除技术——内镜缝合系统联合ESD切除，是一种新的选择吗？","userCount":379,"userId":2763927},{"createTime":1606453807000,"description":"R0/R1状态影响伊马替尼辅助治疗的OS。但如果剔除了肿瘤发生破裂的R1病例，R1对OS没有影响。\nJAMA Surg. 2020 Jun 1;155(6):e200397.  （IF：10.668）","filepathIds":"409564","id":10329,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/f7c05644-385c-43c5-b3ba-f78873e8d1ef.png","attr":"390_390"}],"isRight":0,"researchId":110097422,"researchItemId":2487,"title":"局限期胃肠间质瘤外科手术质量对伊马替尼辅助治疗结局的影响","userCount":361,"userId":2763927},{"createTime":1606453807000,"description":"本文是针对曾发表在JAMA Surg文章的特约述评，该研究发现肿瘤破裂显著增加患者术后复发和死亡的风险。述评专家指出，该研究以胃及小肠GIST为主，对于其它部位GIST的结果仍需探索。\nJAMA Surg. 2020 Jun 1;155(6):e200398.  （IF：10.668）","filepathIds":"409565","id":10330,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/2d4f4b12-4a3a-4015-9192-f2df11af57ec.png","attr":"378_378"}],"isRight":0,"researchId":110097422,"researchItemId":2487,"title":"胃肠道间质瘤中R1切除不差于R0","userCount":309,"userId":2763927},{"createTime":1606453807000,"description":"研究发现平扫组学征象和增强组学征象在高危GIST预测的能力相当，平扫组学征象和影像组学模型都有较高的GIST危险度预测能力。\nClin Transl Med. 2020 Jul 7;10(3):e291. （IF：7.919）","filepathIds":"409566","id":10331,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/60975bc1-1880-4eee-b828-e7e71c5cc463.png","attr":"401_401"}],"isRight":0,"researchId":110097422,"researchItemId":2487,"title":"平扫和增强CT影像组学特征预测GIST危险度效能的比较：一项多中心研究","userCount":1061,"userId":2763927},{"createTime":1606453807000,"description":"研究发现KIT/PDGFRA基因型、发病部位和恶性潜能对于GIST的免疫原性有决定性意义，也是制定GIST治疗方案时需要考虑的因素。\nJCI Insight. 2020 Nov 19;5(22):142560. （IF：6.205）","filepathIds":"409567","id":10332,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/23488297-61bd-4db7-977f-6ec0dc094f42.png","attr":"405_405"}],"isRight":0,"researchId":110097422,"researchItemId":2487,"title":"肿瘤基因型、部位和恶性潜能决定了未经治疗的原发胃肠间质瘤的免疫原性","userCount":307,"userId":2763927},{"createTime":1606453807000,"description":"研究证实肿瘤浸润性三级淋巴样结构（TLS）是OS和TTR的独立预后因素，设计针对TLS的疗法可能为伊马替尼耐药GIST患者提供新的治疗策略。\nOncoimmunology. 2020 Apr 7;9(1):1747339.（IF:5.333）","filepathIds":"409568","id":10333,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/b9f7ce4a-9890-4448-927c-8600bd44f8e8.png","attr":"403_403"}],"isRight":0,"researchId":110097422,"researchItemId":2487,"title":"肿瘤相关三级淋巴结构可预测原发胃肠间质瘤患者的术后结局","userCount":660,"userId":2763927},{"createTime":1606453807000,"description":"在诊断没有明确分化方向的胃肠道间叶性梭形细胞肿瘤时，应考虑到NTRK改变。具有NTRK重排的胃肠道间叶性肿瘤在临床表现和形态学上存在异质性，且似乎很少与GIST有关。\nMod Pathol. 2020 Jul 15. （IF：5.988）","filepathIds":"409569","id":10334,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/5780cb1b-6234-4827-8c90-bba736f1a701.png","attr":"394_394"}],"isRight":0,"researchId":110097422,"researchItemId":2487,"title":"有NTRK重排胃肠道间叶性肿瘤：一项包含8个病例、重点与GIST鉴别的临床病理学、免疫表型及分子研究","userCount":384,"userId":2763927},{"createTime":1606453807000,"description":"研究建立了一个更简单的BRAF突变GIST模型，为平滑肌细胞作为GIST的另一来源提供了确凿证据。\nJ Pathol. 2020 Sep 17.（IF：5.979）","filepathIds":"409570","id":10335,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/c83a545a-74e0-474a-9719-7ed7f03c9bac.png","attr":"395_395"}],"isRight":0,"researchId":110097422,"researchItemId":2487,"title":"一个平滑肌源性、BRAF驱动的GIST小鼠模型：GIST另一种细胞起源的证据","userCount":258,"userId":2763927},{"createTime":1606453807000,"description":"本文重点介绍了PI3K/AKT/mTOR依赖机制在GIST中的研究进展，探讨了mTOR下游信号与GIST发展间的关系，这可能有助于识别新的治疗靶点。\nCancers (Basel) . 2020 Oct 14;12(10):2972. （IF：6.162）","filepathIds":"409571","id":10336,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/0eab5813-9e9d-498b-9d69-461a84d1a8f4.png","attr":"374_374"}],"isRight":0,"researchId":110097422,"researchItemId":2487,"title":"PI3K/AKT/mTOR通路在胃肠间质瘤（GIST）中的治疗潜力：理论基础和进展（综述）","userCount":324,"userId":2763927},{"createTime":1606453807000,"description":"指南结合了国内外最新进展及我国诊疗实际现状，是CSCO撰写的首部GIST指南，瑞派替尼是唯一Ⅰ级推荐用于晚期GIST患者四线治疗。\n组织编写：CSCO指南工作委员会","filepathIds":"409572","id":10337,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/f89f2cdf-7848-418a-bc78-3206580c30f3.png","attr":"515_515"}],"isRight":0,"researchId":110097422,"researchItemId":2487,"title":"中国临床肿瘤学会（CSCO）胃肠间质瘤诊疗指南2020","userCount":993,"userId":2763927},{"createTime":1606453807000,"description":"共识为国内GIST领域同仁提供理论和实践参考，以期进一步提高我国GIST诊疗水平。\n组织编写：中华医学会外科学分会胃肠外科学组，中国医师协会外科医师分会GIST诊疗专业委员会，CSCO GIST专家委员会，中国抗癌协会GIST专业委员会","filepathIds":"409573","id":10338,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/6d8b5412-0986-4e51-97fe-21137b842642.png","attr":"307_307"}],"isRight":0,"researchId":110097422,"researchItemId":2487,"title":"胃肠间质瘤全程化管理中国专家共识（2020版）","userCount":774,"userId":2763927},{"createTime":1606453807000,"description":"2020年岁尾，NCCN GIST指南压轴更新，瑞派替尼作为Ⅰ级推荐用于不可手术切除GIST患者的四线治疗。\n组织编写：NCCN","filepathIds":"409575","id":10339,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/1eaefa70-c2fb-48e2-9993-cf778339417b.png","attr":"415_415"}],"isRight":0,"researchId":110097422,"researchItemId":2487,"title":"美国国家综合癌症网络（NCCN）胃肠间质瘤临床实践指南","userCount":547,"userId":2763927}],"researchId":110097422,"title":"2020 CSCO-CMT胃肠间质瘤十大年度进展开始投票啦！","userCount":2476,"userId":2763927}],"itemsMap":{2487:{"isMultiple":1,"rightOptions":[]}},"joinRange":0,"mark":2,"modifyTime":1606813371000,"researchType":0,"startTime":1606320000000,"title":"2020 CSCO-CMT胃肠间质瘤十大年度进展开始投票啦！","userId":2763927,"voteCount":12416}

200 评论

查看更多

(京)网药械信息备字（2025）第 00153 号 | 京ICP备15004031号-2｜违法和不良信息举报方式：（010）64036988 office@cmt.com.cn

京公网安备 11010202008182号

| 互联网新闻信息服务许可证编号：10120190017

Copyright © 2017-2021 中国医学论坛报社. All rights reserved.